Quick Facts
| DRAXIS Health Inc. is a specialty pharmaceutical company. We provide products internationally in three categories: sterile pharmaceuticals, including liquid and lyophilized (freeze-dried) injectables, specialty non-sterile products and radiopharmaceuticals for diagnostic imaging and treatment. Operations are carried out through the DRAXIS Pharma Division for pharmaceutical contract manufacturing and through the DRAXIMAGE division for the development, production and sale of radiopharmaceutical products. In addition, DRAXIS is developing innovative proprietary radiopharmaceutical products through a targeted research and development program. |
|
| Financial Highlights* | ||||||||||||||||
| (in millions of U.S. dollars except per share amounts) | ||||||||||||||||
| Years ended December 31 | 2006 | 2005 | 2004 | 2003 | 2002 | |||||||||||
|
||||||||||||||||
| Product sales revenues Product gross margin |
83.5 43.6 |
% |
73.0 35.8 |
% |
61.7 35.5 |
% |
40.5 31.6 |
% |
30.3 22.9 |
% |
||||||
| Operating income Operating margin |
15.0 16.8 |
% |
9.8 12.3 |
% |
9.9 14.2 |
% |
6.7 13.6 |
% |
2.9 7.5 |
% |
||||||
| Net income | 11.5 | 7.8 | 8.0 | 4.7 | 3.0 | |||||||||||
| EPS – diluted | $ | 0.28 | $ | 0.18 | $ | 0.19 | $ | 0.13 | $ | 0.08 | ||||||
| Cash and cash equivalents | 21.4 | 12.4 | 5.9 | 10.6 | 4.9 | |||||||||||
| Net operating cash flows | 16.5 | 9.7 | 5.1 | (3.1 | ) | (2.2 | ) | |||||||||
| Capital expenditures | 5.7 | 4.6 | 4.8 | 3.5 | 5.4 | |||||||||||
|
||||||||||||||||
| * from continuing operations | ||||||||||||||||
 |
 |
 |
 |